Objective: A post hoc analysis of two phase III trials was carried out to explore the influence of age and treatment factors on the effect of bortezomib consolidation on progression-free survival (PFS) post autologous stem cell transplantation (ASCT).
Methods: Patients with newly diagnosed multiple myeloma were assigned to one of two trials (ClinicalTrials.gov IDs: NCT00416273, NCT00416208), which were conducted in parallel, based on age (18-60 or 61-75 years, respectively). Following induction and ASCT, patients were randomized 1:1 to four 35-day cycles of bortezomib consolidation (1.6 mg/m IV on days 1, 8, 15, 22) or observation only.
Results: Median PFS with bortezomib consolidation vs observation was 33.6 vs 29.0 months (P = 0.3599) in patients aged 18-60 years (n = 202), and 33.4 vs 26.4 months (P = 0.0073) in patients aged 61-75 years (n = 155), respectively. Bortezomib consolidation post-ASCT appeared to equalize outcomes between older and younger patients who received prior treatment of differing intensity. This suggests that the effect of consolidation may be relative and may depend on the composition and intensity of induction and high-dose therapy.
Conclusion: Older patients receiving less intensive prior treatment could experience a larger PFS benefit from bortezomib consolidation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ejh.13281 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Myelomatous pleural effusion (MPE) is a rare, often treatment-resistant complication of multiple myeloma. Intrapleural bortezomib shows promise but lacks standardized dosing. We report a 62-year-old woman with MPE treated with 1.
View Article and Find Full Text PDFIsatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.
J Clin Oncol
December 2024
Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted in a significant increase of minimal residual disease negativity (MRD-) rates after induction therapy. A total of 662 patients were randomly assigned to receive induction therapy with Isa-RVd (n = 331) or RVd (n = 329), followed by single or tandem autologous stem-cell transplant and second random assignment to maintenance with lenalidomide alone or Isa-lenalidomide.
View Article and Find Full Text PDFSelinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease.
Sci Rep
November 2024
Department of Hematology, Qingdao Hospital, University of Health and Rehabilitation Science, Qingdao Municipal Hospital, Qingdao, 266071, China.
Objective: We aimed to explore the efficacy and safety of Selinexor combined bortezomib, lenalidomide, and dexamethasone (XVRd) protocol in newly diagnosed multiple myeloma with extramedullary disease.
Methods: This is a single-arm, open, observational clinical study. For induction/consolidation(21-day cycles), patients received 8 cycles of XVRd protocol.
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.
Future Oncol
October 2024
Dana-Farber/Partners CancerCare, Harvard Medical School, Boston, MA, USA.
What Is This Summary About?: This summary describes the final analysis of the GRIFFIN study. In this study, participants were newly diagnosed with a type of blood and bone marrow cancer called multiple myeloma, had never received any treatment, and were able to undergo an autologous stem cell transplant. The GRIFFIN study looked at adding the drug daratumumab (D) to a combination of standard treatments called RVd (lenalidomide [R], bortezomib [V], and dexamethasone [d]) during the treatment phases induction and consolidation, followed by daratumumab and lenalidomide (D-R) maintenance.
View Article and Find Full Text PDFA plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.
Future Oncol
November 2024
Hematology Department, University Hospital Hôtel-Dieu, Nantes, France.
Article Synopsis
- - The PERSEUS study analyzed the effects of adding daratumumab (D) to the standard treatment VRd (bortezomib, lenalidomide, and dexamethasone) for adults with newly diagnosed multiple myeloma to see if it could improve outcomes.
- - Participants were divided into two groups: one receiving D-VRd initially followed by D-R maintenance, and the other receiving standard VRd followed by lenalidomide alone.
- - After about four years, results indicated that those who received D-VRd had better treatment responses and were more likely to remain alive and disease-free compared to the VRd-only group, with side effects being consistent with expectations for both treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!